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Abstract
Background: The aim was to evaluate the effects of recombinant human platelet-
derived growth factor-BB (rhPDGF-BB) and recombinant human fibroblast
growth factor-2 (rhFGF-2) on treating periodontal intra-bony defects, compared
to the control (carrier alone).
Methods: Electronic and hand searches were performed to identify eligible stud-
ies. The weighed mean differences of linear defect fill (LDF), probing depth (PD)
reduction, clinical attachment level (CAL) gain and gingival recession (GR) were
calculated using random effect meta-analysis.
Results: The searches yielded 1018 articles, of which seven studies were included.
Only one included study was considered at low risk of bias. The outcomes that
reached statistical significance in comparison to carriers alone included: LDF
(0.95 mm, 95% CI: 0.62–1.28 mm or 20.17%, 95% CI: 11.81–28.54%) and CAL
gain (0.34 mm, 95% CI: 0.03–0.65 mm) for PDGF, and LDF (21.22%, 95% CI:
5.82–36.61%) for FGF-2.
Conclusions: Within the limits of this review, rhPDGF-BB demonstrated
significantly more LDF and CAL gain; rhFGF-2 resulted in significantly higher
percentage of LDF.
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Regeneration of periodontal struc-
tures, characterized by formation of
cementum, alveolar bone and peri-
odontal ligament (PDL), has been a
challenge and a major goal for clini-
cians. Common procedures attempting
to achieve periodontal regeneration
include the use of cell occlusive barrier
membranes (Gottlow et al. 1986),
bone substitutes with (Bowers et al.
1989b, Mellonig 2000) or without
membranes (Froum et al. 1975,
Trombelli & Farina 2008), enamel
matrix derivatives (Heijl et al. 1997)
and root conditioning with chemical
agents (Mariotti 2003). Although
yielding satisfactory results (Karring
et al. 1980, 1984, Gottlow et al. 1986,
Bowers et al. 1989a, Zetterstrom
et al. 1997), there is a high degree of
Conflict of interest and source of
funding statement
TJO and WVG are research investiga-
tors for a clinical trial supported by
Sunstar Corp. The other authors
declare that there are no conflicts of
interest in this study. No external
funding, apart from the authors’ insti-
tution, was available for this study.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd272
J Clin Periodontol 2015; 42: 272–280 doi: 10.1111/jcpe.12354
variability in clinical outcomes fol-
lowing these regenerative procedures
(Aichelmann-Reidy & Reynolds 2008).
The application of growth factors,
shown to be able to promote peri-
odontal regeneration (Lynch et al.
1989, Giannobile et al. 1994, 1996,
Camelo et al. 2003, Nevins et al.
2003, Ridgway et al. 2008), might be
another promising approach.
Dimeric platelet-derived growth
factor (PDGF), including four iso-
forms, is primarily secreted from
platelet a-granules. As a potent agent
for wound healing, rhPDGF-BB has
been extensively used for treating
neuropathic diabetic ulcers (Smiell
et al. 1999). The rhPDGF-BB is also
an FDA approved biological agent
for periodontal regeneration (Nevins
et al. 2005). Mitogenic and chemo-
tactic effects of rhPDGF-BB on peri-
odontal ligament and bone precursor
cells have been demonstrated (Lynch
et al. 1989, Camelo et al. 2003). Sev-
eral human histological studies have
provided proof-of-principle evidence
that rhPDGF-BB results in periodon-
tal regeneration in both periodontal
intra-bony (Nevins et al. 2003, Ridg-
way et al. 2008) and furcation
defects (Camelo et al. 2003, Nevins
et al. 2003, Mellonig et al. 2009).
Clinical studies have shown improve-
ment in probing depth reduction,
rate of clinical attachment level gain
and bone fill (Giannobile & Somerman
2003, Nevins et al. 2005, McGuire
et al. 2006, Jayakumar et al. 2011).
Fibroblast growth factors (FGFs)
belong to a large polypeptide family
with more than 20 member of similar
structures (Ornitz & Itoh 2001).
FGF-2 promotes endothelial cell pro-
liferation and physical organization
of endothelial cells; thus, it enhances
angiogenesis and the growth of new
blood vasculature (Cao et al. 2003).
In addition, FGF-2 exhibits powerful
angiogenic activity and mitogenic
ability on mesenchymal cells (Kao
et al. 2009). Recently, rhFGF-2 has
shown the ability to regenerate perio-
dontal tissues in periodontal intra-
bony defects (Kitamura et al. 2011)
and in surgically created defects in
pre-clinical studies (Murakami et al.
1999, 2003, Takayama et al. 2001,
Nakahara et al. 2003).
With the encouraging evidence of
using rhPDGF-BB and FGF-2 for
treating periodontal defects in clini-
cal trials, a systematic review and
meta-analysis were therefore con-
ducted to summarize the clinical effi-
cacy of these growth factors for
regenerating periodontal intra-bony
defects.
Materials and Methods
Focused question
Does applying rhPDGF-BB or
rhFGF-2 for treating periodontal
intra-bony defects offer better clini-
cal and/or radiographic benefits in
comparison to the carriers alone?
Selection criteria
Human comparative trials attempt-
ing regenerative treatments with the
application of rhPDGF-BB or
rhFGF-2 for at least eight intra-
osseous defects with a minimum
follow-up period of 6 months were
included. Animal studies and human
trials with insufficient information or
lack of data and a proper control
arm were excluded. Potential articles
were reviewed in full-text and con-
firmed for their eligibility.
Search strategy
A search of five electronic databases,
including PubMed, Ovid (MED-
LINE), EMBASE, Web of Science
and Cochrane Center for relevant
studies published was conducted
from 1990 up to June 2013 in accor-
dance with PRISMA guidelines
(Moher et al. 2009). A combination
of MeSH terms and keywords was
designed to identify all pertinent
articles using growth factors for
periodontal regeneration. For this
review, we only considered PDGF-
BB and FGF-2 because they are the
only two clinically tested recombi-
nant human growth factors in the
US for which more than one ran-
domized controlled clinical trial has
been published.
The key terms used in the search
included “growth factor”, “regenera-
tion”, “periodontal defect”, “perio-
dontitis regenerative treatment”,
“guided tissue regeneration”, “biologi-
cal agent”, “bone graft”, “platelet-
derived growth factor” and “fibroblast
growth factor”. Boolean operators,
“OR” and “AND”, were used to com-
bine the literature searches. Further-
more, a search in the references of
included papers was conducted for
publications that were not electroni-
cally identified. Two reviewers (VK
and JM) evaluated potential relevant
articles. Disagreement between the
reviewers was resolved with discus-
sion. The level of agreement between
the reviewers regarding study inclu-
sion was expressed with the kappa
value. In addition, funnel plots were
also used to assess the presence of
publication biases.
Data extraction
Two reviewers extracted the data
(VK and JM). Any disagreement was
resolved between the reviewers fol-
lowing a discussion. The parameters
recorded for each study included
authors’ names, year of publication,
study design, sample size, linear
defect fill (LDF), percentage of defect
fill, probing depth (PD) reduction,
clinical attachment level (CAL) gain,
gingival recession (GR) and follow-
up period. If indicated, authors of
the potentially qualified papers were
contacted for more detailed data.
Risk of bias assessment
The following criteria modified from
the randomized clinical trial checklist
of the Cochrane Center and the
CONSORT statement (Schulz et al.
2010) were used: representative of gen-
eral population, defined inclusions/
exclusions, randomization methods,
allocation concealment method, mask-
ing of the examiner, intervention
different only, participants drop-out
and analysis accounts for patient
losses. The degree of bias were cate-
gorized as: low risk if all the criteria
were met, unclear risk when only one
criterion was missing and high risk if
two or more criteria were missing.
One reviewer (JM) assessed all the
included articles and another exam-
iner (VK) confirmed the results.
Data analysis
The primary outcome was linear
defect fill (LDF) in mm and %, and
the secondary outcome was CAL
gain (mm). PD reduction (mm) and
GR (mm) were the 3rd outcomes.
For the included comparative
studies, the pooled weighted mean
differences (WMD) and the 95%
confidence interval (CI) of each
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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variable were calculated using ran-
dom effect meta-analysis by a com-
puter program (Review Manager,
RevMan, version 5.0., Copenhagen;
The Nordic Cochrane Centre, The
Cochrane Collaboration, 2008). For-
est plots were produced to graphi-
cally represent WMD and 95% CI
for the outcomes of all included
studies using “defect site” as the
analysis unit. In addition, heteroge-
neity among studies was assessed
with the chi-square test, and a p
value <0.05 represents significant
heterogeneity. The reporting of these
meta-analyses adhered to the PRIS-
MA (Preferred Reporting Items for
Systematic Review and Meta-Analy-
ses) statement (Liberati et al. 2009).
Results
The screening process is illustrated
in Fig. S1. Electronic and hand
searches yielded 1018 articles, of
which 11 articles were selected for
full-text evaluation after screening
their titles and abstracts. After full-
text evaluation and cross-referencing,
four articles were excluded. Reasons
for exclusion included redundant
cohorts (Nevins et al. 2013), differ-
ent radiographic analysis and insuffi-
cient data reported (Nevins et al.
2003) and lack of proper control
arms (Ridgway et al. 2008, Rosen
et al.2011). Seven randomized con-
trolled trials (RCT) (Howell et al.
1997, Nevins et al. 2005, Kitamura
et al. 2008, 2011, Jayakumar et al.
2011, Thakare & Deo 2012, Mishra
et al. 2013) were included in
the review. The kappa value for the
inter-reviewer agreement of the
included publications was 0.96. The
main features and conclusions of the
included studies were summarized in
Table 1. The outcomes of various
parameters for each included study
were presented in Table 2.
Features of the included studies
Study design and participant features
In one study (Howell et al. 1997), a
combination of PDGF and IGF-1
(Insulin like growth factor-I) was
used, in four studies (Nevins et al.
2005, Jayakumar et al. 2011, Thakare
& Deo 2012, Mishra et al. 2013)
PDGF-BB was evaluated, and in
two studies (Kitamura et al. 2008,
2011) FGF-2 was applied. Patients T
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between the ages 36–68 were treated
and followed between 6 and
18 months. In one study (Howell
et al. 1997) smokers were not
included in the trial. In one study
(Howell et al. 1997), both furcation
and intra-bony defects were treated;
however, only the results of the
intra-bony defects were used and
analysed for this review.
Defect features
Four studies (Howell et al. 1997,
Kitamura et al. 2008, 2011, Thakare
& Deo 2012) measured defects depth
radiographically, whereas in two
studies (Nevins et al. 2005, Jayaku-
mar et al. 2011) the depth of the
defects was measured directly during
the surgery and in another (Mishra
et al. 2013) bone sounding was used.
In four studies (Nevins et al. 2005,
Kitamura et al. 2008, Jayakumar
et al. 2011, Mishra et al. 2013)
detailed baseline defect configuration
data were available.
Results of the meta-analysis
Results of the primary outcome
The WMD of LDF were 0.95 mm
(95% CI = 0.62–1.28 mm, p < 0.00001)
and 0.17 mm (95% CI = 0.52–
0.86 mm, p = 0.63), respectively,
favouring PDGF but not FGF, (Fig. 1).
A significant heterogeneity among
selected studies using PDGF (p = 0.009)
was noticed. The WMD of LDF (%)
were 20.17% (95% CI = 11.81–
28.54%, p < 0.00001) and 21.22%
(95% CI = 5.82–36.61%, p = 0.007)
for PDGF and FGF groups, respec-
tively, favouring the growth fac-
tor groups (Fig. 2). Significant
heterogeneity among the studies using
PDGF was also found (p = 0.0002).
Results of the secondary outcome
The WMD of CAL gain for the
PDGF group was 0.34 mm (95%
CI = 0.03–0.65 mm), favouring the
PDGF group (p = 0.03) (Fig. 3). For
the FGF-2 group, the WMD of
CAL gain was 0.06 mm (95%
CI = 0.92 to 0.79 mm, p = 0.88).
There was no significant heterogene-
ity among the selected studies using
PDGF-BB (p = 0.08) as well as
FGF-2 (p = 0.08).
Results of the 3rd outcomes
The WMD of PD reduction in the
PDGF group was 0.57 mm (95%
CI = 0.04 to 1.18 mm, p = 0.07)
(Fig. 4) with significant heterogeneity
among selected studies (p = 0.03).
The WMD of GR was 0.18 mm
(95% CI = 0.09 to 0.46 mm)
(p = 0.18) (Supplemental Figure S2)
with no significant heterogeneity
among selected studies (p = 0.59). No
data were available for assessing the
3rd outcomes in the FGF group.
Risk of bias assessment
Two of the included RCT studies
(Thakare & Deo 2012) (Mishra et al.
2013) were identified with a high risk
of bias, one study identified with a
low risk of bias (Jayakumar et al.
2011) and the rest were identified with
an unclear risk of bias (Supplemen-
tary table 1). Funnel plots evaluating
the publication bias of each parame-
ter were prepared (Figs S3–S7).
Discussion
PDGF-BB for promoting periodontal
regeneration
Summary of the main findings
Topical delivery of PDGF resulted
in statistically significantly higher
LDF (0.95 mm or 20.17%) than the
carriers alone, supporting that
PDGF is beneficial in promoting
periodontal defect fill. The amount
of defect fill with PDGF, ranging
from 36.2% to 81%, is comparable
with other regenerative procedures.
Previous studies have reported 34%
bone fill after 6 months (Kilic et al.
1997) and 31% bone fill after 3 years
(Zetterstrom et al. 1997) following
GTR and the use of enamel matrix
derivatives respectively. The differ-
ence in the amount of CAL gain was
0.34 mm, favouring the PDGF
group. A systematic review (Esposito
et al. 2009) showed a mean 1.1 mm
more CAL gain in periodontal
defects treated with enamel matrix
derivatives (EMD) than open flap
debridement alone. However, no
head-to-head comparison study was
Fig. 1. Meta-analysis for comparison of linear defect fill among selected studies. The overall weighted mean difference (WMD) is
0.83 mm (95% CI = 0.47–1.18 mm) in between growth factor group and control group (p < 0.00001).
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available to support if PDGF or
EMD is superior. The modest CAL
gain from PDGF over the control
might be due to the profound effect
of the bone fillers on CAL gain.
The addition of PDGF may
result in more favourable tissue
attachment than vehicle alone or
ß-TCP carrier. Conventional perio-
dontal therapy that reflects the vehi-
cle alone groups healing pattern
most likely will result in repair by
long junctional epithelium (Caton &
Zander 1976, Bowers et al. 1982,
Wikesjo et al. 1992). This epithelial
attachment does not require new
bone formation or cementum on the
root surface but provides resistance
to probing force. Histological studies
(Stahl & Froum 1986, Stavropoulos
et al. 2010) have shown that b-TCP
does not result in periodontal regen-
eration whereas proof-of-principle
has been provided by histological
studies (Camelo et al. 2003, Nevins
et al. 2003, Ridgway et al. 2008) that
PDGF-BB results in periodontal
regeneration in human periodontal
osseous defects.
In one study (Mishra et al. 2013),
the use of PDGF in a methylcellu-
lose gel without an osteoconductive
scaffold did not provide an addi-
tional benefit to the vehicle alone
that underscore the significant role
of delivery method; hence, for
optimizing bioavailability of growth
factors, a proper method of delivery
is important. One study (Rosen et al.
Fig. 2. Meta-analysis for comparison of percentage of defect fill among selected studies. The overall weighted mean difference
(WMD) is 20.70% (95% CI = 14.14–27.26%) in between growth factor group and control group (p < 0.00001).
Fig. 3. Meta-analysis for comparison of CAL gain among selected studies. The overall weighted mean difference (WMD) is
0.26 mm (95% CI = 0.01 to 0.53 mm) in between growth factor group and control group (p = 0.06).
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2011) by utilizing FDBA and b-TCP
as carriers for PDGF yielded a mean
of 4.1 mm CAL gain in treating 50
intra-bony defects. Although it is
arguable that case series studies do
not provide the same level of evi-
dence as RCTs, the favourable out-
come suggested the use of an
osteoconductive carrier with a lower
degradation rate might be beneficial.
Optimal dosage is required for
growth factors to exert the greatest
effect. The 0.3 mg/ml of rhPDGF-BB
resulted in a mean 2.6 mm bone gain,
compared to 1.5 mmwith the 1.0 mg/ml
dose in a multicentre study (Nevins
et al. 2005). The results suggested that
higher dose of PDGF might have a
reduced effect on tissue healing due to
likely feedback inhibition with such
high local doses in a bolus release.
Previous studies (Polson & Heijl
1978, Cortellini et al. 1998) have
shown that there is an increased poten-
tial for better treatment outcomes in
well-contained defects, for example 3–
wall deep and narrow periodontal
defects, following regenerative proce-
dures. In two included RCTs using
PDGF (Nevins et al. 2005, Jayakumar
et al. 2011) although the majority of
the defects were 1 or 2 walls, significant
more LBG and bone formation were
observed in the test groups. Moreover,
subgroup analysis revealed a signifi-
cant increase in bone fill in all defect
types in comparison to b-TCP group
(Nevins et al. 2005). The results sug-
gest the potential of using PDGF in
challenging clinical scenarios.
FGF-2 for promoting periodontal
regeneration
Somewhat less information is avail-
able for the use of FGF-2 in perio-
dontal regeneration. Although there
was significantly more bone fill
(21.2%, 95% CI: 5.82–36.61%) with
the use of FGF-2 in comparison to
vehicle alone groups, the WMD of
CAL gain was not significant (p =
0.88). Histological observation on
the effect of FGF-2 in promoting
periodontal regeneration in humans
has not been studied; however, pre-
clinical studies revealed that FGF-2
induced significant periodontal regen-
eration comprised of new cementum
with Sharpey’s fibres, new functionally
oriented periodontal ligament fibres
and new alveolar bone (Takayama
et al. 2001, Murakami et al. 2003).
In spite of the absence of an osteo-
conductive carrier, the percentage of
bone fill was 39%, 52% and 49% for
0.2%, 0.3% and 0.4%, respectively,
for FGF-2 after 9 months, whereas
this value was 15.86  22.14% for
the vehicle control group. Although
better results with addition of an os-
teoconductive bone substitute may be
expected, to date, no human clinical
trial is available to validate this con-
sideration. The choice of osteocon-
ductive material in combination with
growth factors may have an impor-
tant impact on the outcomes.
Limitations and potential biases
The limitations of this systematic
review include: (1) a fairly low num-
ber of randomized controlled trials
are currently available; (2) risk of
bias was high or unclear in most of
the included studies (3) inconsisten-
cies in methodologies and treatment
modalities among studies and (4) rel-
atively short observational period. In
addition, the sensitivity and stan-
dardization of assessing bone gain
from radiographs might not be opti-
mal. Radiography often underesti-
mates actual bone fill; in addition,
the inherent measurement variability
in the radiographs should be consid-
ered. In most of the included studies,
standardized radiographs were not
employed. Finally, only studies writ-
ten in English were included, which
could introduce a selection bias.
Most of the included studies had
an unclear risk of publication bias
and only one study was recognized
with low risk of bias suggesting that
the results have to be interpreted
with great caution. A common risk
of bias of the included papers is sub-
ject dropout. Nevertheless, all the
studies with subject attrition had
described methods to account for
subject losses. Other biases include a
small subject number that might not
be representative of generation pop-
ulation, no description about the
allocation concealment method, and
calibration of examiners.
Research implications
It is recognized that the delivery sys-
tems for growth factors are continu-
ously evolving (Ramseier et al. 2012).
Given the fact that growth factors
dilute fast in periodontal environ-
ment, the half-lives of them are signif-
icantly impacted (Anusaksathien &
Giannobile 2002, Ramseier et al. 2012);
therefore, future research is war-
ranted for enhancement of delivery
strategies to improve substantiality of
growth factors in periodontal defects.
Clinical implications
The use of PFGF is well supported by
clinical trials. If the cost and benefit
Fig. 4. Meta-analysis for comparison of PD reduction among selected studies. The overall weighted mean difference (WMD) is
0.57 mm (95% CI = 0.04 to 1.18 mm) in between growth factor group and control group (p = 0.07).
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are justifiable, PDGF can be an
option to maximize the healing poten-
tial in periodontal defects, especially
for teeth of strategic importance and
challenging periodontal defects. FGF
might be another biological agent
with a great potential for augmenting
periodontal healing but more clinical
trials are needed.
Conclusions
For treating intra-bony defects,
applying PDGF-BB demonstrated
significantly more defect fill and
CAL gain than carriers alone. Con-
trolled clinical trials on FGF-2 are
limited; the available evidence sug-
gested that FGF-2 resulted in signifi-
cantly more defect fill (%) but not in
CAL gain. Therefore, PDGF may be
used to maximize the regenerative
outcomes, provided that the cost/
benefit is justified. Future research
can be focused on engineering more
suitable carriers that can deliver bio-
logical agents more effectively.
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Table S1. Risk assessment of publi-
cation bias for the included RCTs.
Figure S1. Flow chart illustrating
study selection for the systematic
review.
Figure S2. Meta-analysis for com-
parison of the amount of gingival
recession among selected studies.
The overall weighted mean differ-
ence (WMD) is 0.18 mm (95%
CI = 0.09 to 0.46 mm) in between
growth factor group and control
group (p = 0.18).
Figure S3. Funnel plot illustrating
publication bias for linear bone
growth.
Figure S4. Funnel plot illustrating
publication bias for the percentage
of bone fill.
Figure S5. Funnel plot illustrating
publication bias for the clinical
attachment level gain.
Figure S6. Funnel plot illustrating
publication bias for probing depth
reduction.
Figure S7. Funnel plot illustrating
publication bias for gingival reces-
sion.
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Clinical Relevance
Scientific rationale for the study:
Applying biological factors such as
growth factors for periodontal
regenerative procedures is an
emerging technology for clinical
application.
Principal findings: rhPDGF-BB and
rhFGF-2 result in greater linear
defect fill and bone fill (%) than
standard of care therapies for treat-
ment of intra-bony periodontal
defects.
Practical implications: Local
administration of rhPDGF-BB or
rhFGF-2 to periodontal osseous
defects provides promising clinical
benefits to repair lost periodontal
tissues.
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